Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| Teme: | |
| Online dostop: | Connect to this object online. |
| Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Kopija 1 | Prosto |